USPTO Patent Grant: Synthetic Modified Vaccinia Ankara Based Coronavirus Vaccines

ChangeBridge: Patent Grants - Biotech (C12N)

Published March 24th, 2026

Detected March 24th, 2026

Summary

The USPTO has granted patent US12584146B2 to City of Hope for synthetic modified vaccinia Ankara (SMVA) based vaccine compositions designed to prevent or treat coronavirus infections. The patent covers novel vaccine formulations and methods of production.

View original document View source feed page

What changed

The United States Patent and Trademark Office (USPTO) has granted patent US12584146B2 to City of Hope. This patent covers synthetic modified vaccinia Ankara (SMVA) based vaccine compositions and methods for preventing or treating coronavirus infections. The invention involves using SMVA as a vector for delivering DNA sequences encoding coronavirus antigens, subunits, or fragments thereof, with specific details on DNA fragment assembly and insertion sites within the MVA genome.

This patent grant represents a new intellectual property asset in the field of vaccine development. While it does not impose direct compliance obligations on other entities, it may influence research and development strategies for companies working on similar vaccine technologies. Companies operating in the biotechnology and pharmaceutical sectors should be aware of this granted patent when developing or commercializing coronavirus vaccines, particularly those utilizing MVA vectors or similar delivery mechanisms, to avoid potential infringement.

Source document (simplified)

← USPTO Patent Grants

Synthetic modified vaccinia Ankara (SMVA) based coronavirus vaccines

Grant US12584146B2 Kind: B2 Mar 24, 2026

Assignee

CITY OF HOPE

Inventors

Don J. Diamond, Felix Wussow, Flavia Chiuppesi

Abstract

Synthetic MVA-based vaccine compositions for preventing or treating a virus infection such as a coronavirus infection and methods of producing the vaccines. The vaccine compositions include (i) either a single DNA fragment that includes the entire genome of MVA, or two or more DNA fragments, each including a partial sequence of the genome of the MVA such that the two or more DNA fragments, when expressed in the host cell upon co-transfection, are assembled sequentially and comprise the full-length sequence of the MVA genome, and (ii) one or more DNA sequences encoding one or more human coronavirus antigens, subunits, or fragments thereof inserted in one or more insertion sites of the MVA. The antigens, subunits, or fragments thereof are expressed in the host cell upon transfection of the one or more DNA fragments.

CPC Classifications

C12N 15/86 C12N 2710/24143 C12N 2710/24171 C12N 2770/20022 C12N 2770/20034 C12N 2770/20071 C12N 15/00 A61K 39/215 A61K 2039/53 A61K 2039/575 A61K 2039/545 A61K 2039/572 A61K 39/12 A61P 31/14 C07K 14/005 C07K 2319/02 C07K 2319/03